Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


18.02.2019

1 AJR Am J Roentgenol
1 Am J Surg
1 Ann Oncol
1 Ann Surg Oncol
2 BMC Cancer
1 Br J Cancer
1 Breast Cancer
3 Breast Cancer Res
6 Breast Cancer Res Treat
5 Breast J
4 Cancer
4 Cancer Lett
5 Cancer Res
5 Clin Breast Cancer
4 Clin Cancer Res
1 Curr Treat Options Oncol
1 Eur J Cancer
3 Eur J Surg Oncol
5 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Natl Cancer Inst
1 J Surg Oncol
2 Lancet
2 Lancet Oncol
3 N Engl J Med
1 Oncogene
1 PLoS Comput Biol
5 PLoS One
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. LIN LLY, Gao Y, Lewin AA, Toth HK, et al
    Overstated Harms of Breast Cancer Screening? A Large Outcomes Analysis of Complications Associated With 9-Gauge Stereotactic Vacuum-Assisted Breast Biopsy.
    AJR Am J Roentgenol. 2019 Feb 11:1-8. doi: 10.2214/AJR.18.20421.
    PubMed     Text format     Abstract available


    Am J Surg

  2. CHATTERJEE A, Asban A, Jonczyk M, Chen L, et al
    A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with free flap reconstruction in the treatment of breast cancer.
    Am J Surg. 2019 Jan 31. pii: S0002-9610(18)31174.
    PubMed     Text format     Abstract available


    Ann Oncol

  3. TELLI ML, Vinayak S
    Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
    Ann Oncol. 2019 Feb 7. pii: 5308591. doi: 10.1093.
    PubMed     Text format    


    Ann Surg Oncol

  4. BATENI SB, Davidson AJ, Arora M, Daly ME, et al
    Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis.
    Ann Surg Oncol. 2019 Feb 13. pii: 10.1245/s10434-019-07159.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2019;19:152.
    PubMed     Text format     Abstract available

  6. PETITJEAN A, Smith-Palmer J, Valentine W, Tehard B, et al
    Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    BMC Cancer. 2019;19:140.
    PubMed     Text format     Abstract available


    Br J Cancer

  7. FUJIWARA Y, Mukai H, Saeki T, Ro J, et al
    A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0391.
    PubMed     Text format     Abstract available


    Breast Cancer

  8. LAI HL, Chen CI, Lu CY, Yao YC, et al
    Relationships among personality, coping, and concurrent health-related quality of life in women with breast cancer.
    Breast Cancer. 2019 Feb 12. pii: 10.1007/s12282-019-00954.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  9. NGUYEN B, Venet D, Lambertini M, Desmedt C, et al
    Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.
    Breast Cancer Res. 2019;21:25.
    PubMed     Text format     Abstract available

  10. SMITH NG, Gyanchandani R, Shah OS, Gurda GT, et al
    Targeted mutation detection in breast cancer using MammaSeq.
    Breast Cancer Res. 2019;21:22.
    PubMed     Text format     Abstract available

  11. HSU YL, Yen MC, Chang WA, Tsai PH, et al
    CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.
    Breast Cancer Res. 2019;21:23.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  12. YANG SX, Polley EC
    Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05142.
    PubMed     Text format     Abstract available

  13. STAVRAKA C, Pouptsis A, Okonta L, DeSouza K, et al
    Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05144.
    PubMed     Text format     Abstract available

  14. LAN Y, Zhao E, Luo S, Xiao Y, et al
    Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
    Breast Cancer Res Treat. 2019 Feb 9. pii: 10.1007/s10549-019-05153.
    PubMed     Text format     Abstract available

  15. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Feb 15. pii: 10.1007/s10549-019-05165.
    PubMed     Text format     Abstract available

  16. GREGOROWITSCH ML, Ghedri A, Young-Afat DA, Bijlsma R, et al
    The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05149.
    PubMed     Text format     Abstract available

  17. KOTSOPOULOS J, Lubinski J, Lynch HT, Tung N, et al
    Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05162.
    PubMed     Text format     Abstract available


    Breast J

  18. PAPPOT H, Baeksted C, Knoop A, Mitchell SA, et al
    Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminolo
    Breast J. 2019 Feb 13. doi: 10.1111/tbj.13204.
    PubMed     Text format     Abstract available

  19. AL ALI A, Garrido I, Le Guellec S, Duazo-Cassin L, et al
    Rapidly growing breast desmoid tumor with intra-thoracic involvement after reconstructive surgery for breast cancer.
    Breast J. 2019 Feb 12. doi: 10.1111/tbj.13212.
    PubMed     Text format     Abstract available

  20. NAIR NS, Parmar V, Badwe RA
    Intent of surgery of the primary tumor in metastatic breast cancer remains palliative.
    Breast J. 2019 Feb 13. doi: 10.1111/tbj.13224.
    PubMed     Text format    

  21. VOHRA NA, Brinkley J, Kachare S, Muzaffar M, et al
    Reply to "Letter to the Editor" intent of surgery of the primary tumor in metastatic breast cancer remains palliative.
    Breast J. 2019 Feb 13. doi: 10.1111/tbj.13225.
    PubMed     Text format    

  22. ROBERSON PNE, Southerland A, Mitchel H, Lloyd J, et al
    Factors predicting medication prescription adherence in Appalachian breast cancer patients.
    Breast J. 2019 Feb 13. doi: 10.1111/tbj.13227.
    PubMed     Text format    


    Cancer

  23. BALAZY KE, Benitez CM, Gutkin PM, Jacobson CE, et al
    Association between primary language, a lack of mammographic screening, and later stage breast cancer presentation.
    Cancer. 2019 Feb 15. doi: 10.1002/cncr.32027.
    PubMed     Text format     Abstract available

  24. HENDRICK RE, Baker JA, Helvie MA
    Breast cancer deaths averted over 3 decades.
    Cancer. 2019 Feb 11. doi: 10.1002/cncr.31954.
    PubMed     Text format     Abstract available

  25. DUFFY SW, Smith RA, Tabar L, Dean PB, et al
    Reply to The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32007.
    PubMed     Text format    

  26. GIANNAKEAS V, Narod SA
    The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.32008.
    PubMed     Text format    


    Cancer Lett

  27. HE Q, Xue S, Tan Y, Zhang L, et al
    Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
    Cancer Lett. 2019 Feb 8. pii: S0304-3835(19)30070.
    PubMed     Text format     Abstract available

  28. MA F, Liu X, Zhou S, Li W, et al
    Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30080.
    PubMed     Text format     Abstract available

  29. MARQUEZ-GARBAN DC, Gorrin-Rivas M, Chen HW, Sterling C Jr, et al
    Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30081.
    PubMed     Text format     Abstract available

  30. AHMED K, Koval A, Xu J, Bodmer A, et al
    Towards the first targeted therapy for triple-negative breast cancer: repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30090.
    PubMed     Text format     Abstract available


    Cancer Res

  31. BHOLA NE, Jansen VM, Bafna S, Giltnane JM, et al
    Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.
    Cancer Res. 2019;79:876.
    PubMed     Text format    

  32. HONG BS, Ryu HS, Kim N, Kim J, et al
    Tumor suppressor microRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer.
    Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-0891.
    PubMed     Text format     Abstract available

  33. HANKER AB, Estrada MV, Bianchini G, Moore PD, et al
    Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
    Cancer Res. 2019;79:873.
    PubMed     Text format    

  34. JANSEN VM, Bhola NE, Bauer JA, Formisano L, et al
    Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Cancer Res. 2019;79:874.
    PubMed     Text format    

  35. BHOLA NE, Jansen VM, Koch JP, Li H, et al
    Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
    Cancer Res. 2019;79:875.
    PubMed     Text format    


    Clin Breast Cancer

  36. ALTUNDAG DK
    Prognostic Significance of Obesity and Diabetes Mellitus in Women With Brain Metastases From Breast Cancer Should Be Revisited.
    Clin Breast Cancer. 2019 Jan 23. pii: S1526-8209(19)30021.
    PubMed     Text format    

  37. PAPLOMATA E, Zelnak A, Santa-Maria CA, Liu Y, et al
    Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
    Clin Breast Cancer. 2019 Jan 3. pii: S1526-8209(18)30637.
    PubMed     Text format     Abstract available

  38. SYMONDS L, Linden H, Gadi V, Korde L, et al
    Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Clin Breast Cancer. 2018 Dec 14. pii: S1526-8209(18)30655.
    PubMed     Text format     Abstract available

  39. MOTAWI TMK, Zakhary NI, Darwish HA, Abdalla HM, et al
    Significance of Serum Survivin and -31G/C Gene Polymorphism in the Early Diagnosis of Breast Cancer in Egypt.
    Clin Breast Cancer. 2019 Jan 6. pii: S1526-8209(18)30704.
    PubMed     Text format     Abstract available

  40. CACHO-DIAZ B, Spinola-Marono H, Reynoso N, Gonzalez-Aguilar A, et al
    Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.
    Clin Breast Cancer. 2019 Jan 7. pii: S1526-8209(18)30766.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  41. UNNI N, Sudhan DR, Arteaga CL
    Correction: Neratinib: Inching Up on the Cure Rate of HER2(+) Breast Cancer?
    Clin Cancer Res. 2019;25:1430.
    PubMed     Text format    

  42. LOI S, Dushyanthen S, Beavis PA, Salgado R, et al
    Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2019;25:1437.
    PubMed     Text format    

  43. FORMISANO L, Stauffer KM, Young CD, Bhola NE, et al
    Correction: Association of FGFR1 with ERalpha Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER(+) Breast Cancer.
    Clin Cancer Res. 2019;25:1433.
    PubMed     Text format    

  44. IIZUKA A, Nonomura C, Ashizawa T, Kondou R, et al
    A T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targets human breast cancer.
    Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-17-3123.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  45. RAGHUNATH A, Desai K, Ahluwalia MS
    Current Treatment Options for Breast Cancer Brain Metastases.
    Curr Treat Options Oncol. 2019;20:19.
    PubMed     Text format     Abstract available


    Eur J Cancer

  46. EKHOLM M, Bendahl PO, Ferno M, Nordenskjold B, et al
    Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
    Eur J Cancer. 2019;110:53-61.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  47. ESGUEVA A, Rodriguez-Revuelto R, Espinosa-Bravo M, Salazar JP, et al
    Learning curves in intraoperative ultrasound guided surgery in breast cancer based on complete breast cancer excision and no need for second surgeries.
    Eur J Surg Oncol. 2019 Feb 1. pii: S0748-7983(19)30040.
    PubMed     Text format     Abstract available

  48. RUSSO L, Maltese A, Betancourt L, Romero G, et al
    Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy.
    Eur J Surg Oncol. 2019 Feb 4. pii: S0748-7983(19)30248.
    PubMed     Text format     Abstract available

  49. MICCO RD, Zuber V, Fiacco E, Carriero F, et al
    Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
    Eur J Surg Oncol. 2019 Jan 31. pii: S0748-7983(19)30245.
    PubMed     Text format     Abstract available


    Int J Cancer

  50. DE KRUIJFF IE, Sieuwerts AM, Onstenk W, Jager A, et al
    Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    Int J Cancer. 2019 Feb 13. doi: 10.1002/ijc.32209.
    PubMed     Text format     Abstract available

  51. JAYASEKARA H, MacInnis RJ, Chamberlain JA, Dite GS, et al
    Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.
    Int J Cancer. 2019 Feb 16. doi: 10.1002/ijc.32214.
    PubMed     Text format     Abstract available

  52. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Assessment and Management of Bone Health in Women with Early Breast Cancer Receiving Endocrine Treatment in the DATA Study.
    Int J Cancer. 2019 Feb 12. doi: 10.1002/ijc.32205.
    PubMed     Text format     Abstract available

  53. MANDRIK O, Zielonke N, Meheus F, Severens JLH, et al
    Systematic reviews as a "lens of evidence": determinants of benefits and harms of breast cancer screening.
    Int J Cancer. 2019 Feb 14. doi: 10.1002/ijc.32211.
    PubMed     Text format     Abstract available

  54. NAPOLITANO G, Lynge E, Lillholm M, Vejborg I, et al
    Change in mammographic density across birth cohorts of Dutch breast cancer screening participants.
    Int J Cancer. 2019 Feb 14. doi: 10.1002/ijc.32210.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  55. VAN DEN BOGAARD VAB, van Luijk P, Hummel YM, van der Meer P, et al
    Cardiac Function After Radiotherapy for Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 11. pii: S0360-3016(19)30193.
    PubMed     Text format     Abstract available


    J Clin Oncol

  56. ATEMA V, van Leeuwen M, Kieffer JM, Oldenburg HSA, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2019 Feb 14:JCO1800655. doi: 10.1200/JCO.18.00655.
    PubMed     Text format     Abstract available

  57. DOWSETT M, Turner N
    Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.
    J Clin Oncol. 2019 Feb 11:JCO1801412. doi: 10.1200/JCO.18.01412.
    PubMed     Text format    

  58. PAN K, Bosserman LD, Chlebowski RT
    Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    J Clin Oncol. 2019 Feb 11:JCO1801360. doi: 10.1200/JCO.18.01360.
    PubMed     Text format    


    J Natl Cancer Inst

  59. COHN BA, Cirillo PM, Terry MB
    DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.
    J Natl Cancer Inst. 2019 Feb 13. pii: 5299924. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Surg Oncol

  60. PARK KU, Kyrish K, Terrell J, Yi M, et al
    Surgeon perception versus reality: Opioid use after breast cancer surgery.
    J Surg Oncol. 2019 Feb 8. doi: 10.1002/jso.25395.
    PubMed     Text format     Abstract available


    Lancet

  61. HURVITZ SA
    Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
    Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.
    PubMed     Text format    


  62. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
    Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
    PubMed     Text format     Abstract available


    Lancet Oncol

  63. LOI S, Giobbie-Hurder A, Gombos A, Bachelot T, et al
    Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(18)30812.
    PubMed     Text format     Abstract available

  64. PEOPLES GE
    Improving the outcomes of checkpoint inhibitors in breast cancer.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(19)30068.
    PubMed     Text format    


    N Engl J Med

  65. HAYES DF
    Further Progress for Patients with Breast Cancer.
    N Engl J Med. 2019;380:676-677.
    PubMed     Text format    

  66. PROWELL TM, Beaver JA, Pazdur R
    Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.
    N Engl J Med. 2019;380:612-615.
    PubMed     Text format    


  67. Lymphedema after Breast Cancer Treatment.
    N Engl J Med. 2019;380:694.
    PubMed     Text format    


    Oncogene

  68. BLOCK I, Muller C, Sdogati D, Pedersen H, et al
    CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3.
    Oncogene. 2019 Feb 12. pii: 10.1038/s41388-019-0739.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  69. RUFFALO M, Thomas R, Chen J, Lee AV, et al
    Network-guided prediction of aromatase inhibitor response in breast cancer.
    PLoS Comput Biol. 2019;15:e1006730.
    PubMed     Text format     Abstract available


    PLoS One

  70. COLLIN LJ, McCullough LE, Conway K, White AJ, et al
    Reproductive characteristics modify the association between global DNA methylation and breast cancer risk in a population-based sample of women.
    PLoS One. 2019;14:e0210884.
    PubMed     Text format     Abstract available

  71. PEARLMAN A, Rahman MT, Upadhyay K, Loke J, et al
    Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions.
    PLoS One. 2019;14:e0211737.
    PubMed     Text format     Abstract available

  72. MURPHY C, Muscat A, Ashley D, Mukaro V, et al
    Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
    PLoS One. 2019;14:e0210891.
    PubMed     Text format     Abstract available

  73. MEYER SB, Foley K, Olver I, Ward PR, et al
    Alcohol and breast cancer risk: Middle-aged women's logic and recommendations for reducing consumption in Australia.
    PLoS One. 2019;14:e0211293.
    PubMed     Text format     Abstract available

  74. LYNG FM, Traynor D, Nguyen TNQ, Meade AD, et al
    Discrimination of breast cancer from benign tumours using Raman spectroscopy.
    PLoS One. 2019;14:e0212376.
    PubMed     Text format     Abstract available


    Radiology

  75. LI H, Mendel KR, Lan L, Sheth D, et al
    Digital Mammography in Breast Cancer: Additive Value of Radiomics of Breast Parenchyma.
    Radiology. 2019 Feb 12:181113. doi: 10.1148/radiol.2019181113.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: